Company intelligence / Profile preview

Psyrin

San Francisco, California, United States

Ownership: Private
Development stage: Preclinical

Overview

Siren Biotechnology is developing a novel class of cancer therapeutics that combine AAV gene therapy with cytokine immunotherapy. Their lead program targets high-grade glioma using an AAV vector to deliver immune-stimulating cytokines directly into tumors. Preclinical data are encouraging, and the company aims to initiate clinical trials after regulatory engagement later this year.

Therapeutic areas: Oncology
Modalities: Gene therapyCytokine immunotherapyAdeno-associated viral (AAV) vector-based therapyBiologic
Industry: Biotech

Partnerships

Catalent – process development and cGMP manufacturing of AAV gene therapiesWhiteLab Genomics – AI-powered indication discovery platform partnership for new targets in oncology using AAV gene therapies

Beyond the preview

Go deeper on Psyrin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Psyrin.

Explore the full profile